<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>辉瑞将Covid疫苗提交FDA批准，于12月分发Pfizer submits Covid vaccine to FDA for approval, to distribute in December</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">Pfizer submits Covid vaccine to FDA for approval, to distribute in December<br/>辉瑞将Covid疫苗提交FDA批准，于12月分发</h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2020-11-21 19:48:32</div><div class="page_narrow text-break page_content"><p>In addition to today’s submission to the FDA, the companies have already initiated rolling submissions across the globe including in Australia, Canada, Europe, Japan and the U.K., and plan to submit applications immediately to other regulatory agencies around the world</p><p>除了今天提交给FDA的文件外，两家公司还已经在澳大利亚，加拿大，欧洲，日本和英国等全球范围内发起了滚动提交文件，并计划立即向全球其他监管机构提交申请</p><p> Based on current projections, the companies expect to produce globally up to 50 million doses in 2020 and up to 1.3 billion doses by the end of 2021; the companies will be ready to distribute the vaccine within hours after authorization</p><p>根据目前的预测，两家公司预计到2020年全球将生产5000万剂，到2021年底将生产13亿剂。公司将在授权后数小时内准备分发疫苗</p><p> BNT162b2 demonstrated a vaccine efficacy rate of 95%, with no serious safety concerns observed to date</p><p>BNT162b2的疫苗功效率为95％，迄今为止尚未发现严重的安全隐患</p><p> NEW YORK &amp; MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and  BioNTech SE (Nasdaq: BNTX) announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of December 2020.</p><p>辉瑞公司（纽约证券交易所代码：PFE）和BioNTech SE公司（纳斯达克股票代码：BNTX）今天宣布，他们将向美国食品药品监督管理局（FDA）提交紧急申请他们的针对SARS-CoV-2的mRNA疫苗候选物BNT162b2的授权（EUA），将有可能在2020年12月中旬至美国之前在美国高危人群中使用该疫苗。</p><p>  The submission is based on a vaccine efficacy rate of 95% (p&lt;0.0001) demonstrated in the companies’ Phase 3 clinical study in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 7 days after the second dose. The first primary objective analysis was based on 170 confirmed cases of COVID-19. This submission also is supported by solicited safety data from a randomized subset of approximately 8,000 participants ≥18 years of age and unsolicited safety data from approximately 38,000 trial participants who have been followed for a median of two months following the second dose of the vaccine candidate. The submission also includes solicited safety data on approximately 100 children 12-15 years of age. Approximately 42% of global participants and 30% of U.S. participants in the Phase 3 study have racially and ethnically diverse backgrounds, and 41% of global and 45% of U.S. participants are 56-85 years of age. To date, the Data Monitoring Committee (DMC) for the study has not reported any serious safety concerns related to the vaccine.</p><p>该报告是基于公司的3期临床研究中未感染SARS-CoV-2感染者（第一主要目标）以及既往有或未患有SARS的受试者中疫苗有效率为95％（p <0.0001）得出的。 -CoV-2感染（第二主要目标），在每种情况下均从第二次给药后7天开始测量。最初的主要客观分析是基于170例确诊的COVID-19病例。此提交还受到来自约8,000名≥18岁参与者的随机子集的征集安全性数据和来自大约38,000名在第二次接种疫苗后接受了中位数随访两个月的试验参与者的未经请求的安全性数据的支持。提交的文件还包括约100名12-15岁儿童的安全数据。在第三阶段研究中，大约42％的全球参与者和30％的美国参与者具有不同种族和种族背景，并且41％的全球参与者和45％的美国参与者年龄在56-85岁之间。迄今为止，该研究的数据监控委员会（DMC）尚未报告与疫苗有关的任何严重的安全隐患。</p><p> “Our work to deliver a safe and effective vaccine has never been more urgent, as we continue to see an alarming rise in the number of cases of COVID-19 globally. Filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world and we now have a more complete picture of both the efficacy and safety profile of our vaccine, giving us confidence in its potential,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We look forward to the upcoming Vaccines and Related Biological Products Advisory Committee discussion and continue to work closely with the FDA and regulatory authorities worldwide to secure authorization of our vaccine candidate as quickly as possible.”</p><p>“我们提供安全有效的疫苗的工作从未像现在这样紧迫，因为我们继续看到全球COVID-19病例数量惊人地增加。在美国归档代表了我们向世界提供COVID-19疫苗的过程中的关键里程碑，我们现在对疫苗的功效和安全性有了更全面的了解，这使我们对其疫苗充满信心。”辉瑞公司董事长兼首席执行官Albert Bourla。 “我们期待着疫苗和相关生物产品咨询委员会的讨论，并继续与FDA和全球监管机构紧密合作，以确保尽快获得我们候选疫苗的授权。”</p><p> “Filing for Emergency Use Authorization in the U.S. is a critical step in making our vaccine candidate available to the global population as quickly as possible,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “We intend to continue to work with regulatory agencies worldwide to enable the rapid distribution of our vaccine globally. As a company located in Germany in the heart of Europe, our interactions with the European Medicines Agency (EMA) are of particular importance to us and we have continuously provided data to them as part of our rolling review process.”</p><p>BioNTech首席执行官兼联合创始人Ugur Sahin，医学博士说：“在美国，为紧急使用提供许可是向全球人群尽快提供我们的候选疫苗的关键一步。” “我们打算继续与世界各地的监管机构合作，以实现我们疫苗在全球的快速分销。作为一家位于欧洲心脏地带的德国公司，我们与欧洲药品管理局（EMA）的互动对我们尤为重要，并且在滚动审核流程中，我们不断向他们提供数据。”</p><p> The companies have already initiated rolling submissions with several regulatory agencies around the world, including the EMA and the Medicines &amp; Healthcare Products Regulatory Agency (MHRA) in the United Kingdom, and intend to submit applications to other regulatory agencies worldwide in the coming days. In some cases, governments may have regulatory pathways similar to an EUA. The companies will be ready to distribute the vaccine candidate within hours after authorization.</p><p>两家公司已经开始与包括EMA和英国药品与保健产品监管局（MHRA）在内的全球多个监管机构进行滚动提交，并打算在未来几天内向全球其他监管机构提交申请。在某些情况下，政府可能具有类似于EUA的监管途径。两家公司将准备在授权后数小时内分发候选疫苗。</p><p> Pfizer and BioNTech are extremely grateful to the study volunteers and investigative site staff in the clinical trial program, as their involvement was crucial to today’s important milestone in the companies’ efforts to address the COVID-19 global pandemic.</p><p>辉瑞和BioNTech非常感谢临床试验计划中的研究志愿者和研究人员，因为他们的参与对于当今公司应对COVID-19全球大流行的重要里程碑至关重要。</p><p> The BNT162b2 vaccine candidate is not currently approved for distribution anywhere in the world. Both collaborators are committed to developing this novel vaccine with preclinical and clinical data at the forefront of all their decision making.</p><p>BNT162b2候选疫苗目前尚未批准在世界任何地方分发。两位合作者都致力于开发具有临床前和临床数据的新型疫苗，这是他们所有决策的重中之重。</p><p>  While Pfizer and BioNTech await potential authorization or approval from regulatory agencies, the companies continue to work in collaboration with governments and Ministries of Health around the world that will distribute the vaccine, subject to authorization or approval, to help ensure it can reach those most in need as quickly as possible.</p><p>当辉瑞和BioNTech等待监管机构的潜在授权或批准时，两家公司将继续与世界各地的政府和卫生部合作，在获得授权或批准的情况下分发疫苗，以帮助确保其能够达到需要尽快。</p><p> Pfizer is bringing its leading in-house manufacturing capabilities to this effort, with the ability and experience to quickly scale, manufacture and distribute large quantities of vaccine at high quality, leveraging multiple sites in the U.S. and Europe, and complementing the mRNA manufacturing expertise of BioNTech, gained over almost a decade. Pfizer and BioNTech’s combined manufacturing network has the potential to supply up to 50 million vaccine doses globally in 2020 and up to 1.3 billion doses by the end of 2021 (subject to clinical success, manufacturing capacity, and regulatory approval or authorization).</p><p>辉瑞（Pfizer）将其领先的内部制造能力用于这一工作，具有在美国和欧洲的多个地点利用高质量和快速规模化，制造和分发大量疫苗的能力和经验，并补充了辉瑞公司的mRNA制造专业知识BioNTech，成长了将近十年。辉瑞和BioNTech的联合制造网络有潜力在2020年全球提供多达5000万剂疫苗，到2021年底将提供多达13亿剂疫苗（取决于临床成功，制造能力以及监管机构的批准或授权）。</p><p> Pfizer has vast experience and expertise in cold-chain shipping and has an established infrastructure to supply the vaccine worldwide, including distribution hubs that can store vaccine doses for up to six months. The company has developed specially designed, temperature-controlled shippers for the BNT162b2 vaccine candidate, which can maintain recommended storage conditions (-70°C ±10°C) up to 15 days. Each shipper contains a GPS-enabled thermal sensor to track the location and temperature of each vaccine shipment. Once thawed, the vaccine vial can be stored for up to 5 days at refrigerated (2 - 8 oC) conditions.</p><p>辉瑞在冷链运输方面拥有丰富的经验和专业知识，并拥有完善的基础设施，可以在全球范围内提供疫苗，包括可以将疫苗剂量最多保存六个月的分销中心。该公司为BNT162b2候选疫苗开发了专门设计的，温度可控的托运人，可以将推荐的存储条件（-70°C±10°C）保持长达15天。每个托运人都包含一个启用GPS的热传感器，以跟踪每次疫苗运送的位置和温度。解冻后，疫苗小瓶可在冷藏（2-8 oC）条件下最多保存5天。</p><p> From the start of the research program earlier this year, Pfizer and BioNTech have successfully supplied and distributed their investigational vaccine to more than 150 clinical trial sites across the U.S., as well as Europe, Latin America, and South Africa. Based on their collective experience, the companies believe in their capability to distribute the vaccine globally upon approval or authorization.</p><p>从今年早些时候开始研究计划以来，辉瑞和BioNTech已成功地向美国，欧洲，拉丁美洲和南非的150多个临床试验场所提供并分发了他们的研究用疫苗。根据他们的集体经验，这些公司相信他们具有在获得批准或授权后在全球范围内分发疫苗的能力。</p><p>  The Phase 3 clinical trial of BNT162b2, which is based on BioNTech&#39;s proprietary mRNA technology, began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate as of November 13, 2020. A breakdown of the diversity of clinical trial participants can be found  here from approximately 150 clinical trials sites in the U.S., Germany, Turkey, South Africa, Brazil and Argentina. Participants will continue to be monitored for long-term protection and safety for an additional two years after their second dose.</p><p>基于BioNTech专有的mRNA技术的BNT162b2的3期临床试验于7月27日开始，迄今已招募了43,661名参与者，截至2020年11月13日，其中41,135人已接受了第二剂候选疫苗。可以在美国，德国，土耳其，南非，巴西和阿根廷的约150个临床试验站点找到众多临床试验参与者。在第二次服药后的两年内，将继续对参与者进行长期保护和安全性监测。</p><p> Pfizer and BioNTech plan to submit the efficacy and safety data from the study for peer-review in a scientific journal once analysis of the data is completed.</p><p>辉瑞和BioNTech计划在完成数据分析后，将研究的功效和安全性数据提交科学期刊进行同行评审。</p><p>  At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world&#39;s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at  www.Pfizer.com. In addition, to learn more, please visit us on  www.Pfizer.com and follow us on Twitter at  @Pfizer and  @Pfizer News,  LinkedIn,  YouTube and like us on Facebook at  Facebook.com/Pfizer.</p><p>在辉瑞公司，我们运用科学和全球资源为人们提供疗法，以延长并显着改善他们的生活。我们致力于为包括创新药物和疫苗在内的保健产品的发现，开发和制造设定质量，安全性和价值的标准。辉瑞公司的同事每天都在发达市场和新兴市场开展工作，以改善挑战当今时代最令人恐惧的疾病的保健，预防，治疗和治愈方法。作为我们作为全球领先的创新生物制药公司之一的职责，我们与医疗保健提供者，政府和当地社区合作，在全球范围内支持和扩展获得可靠，负担得起的医疗保健的途径。 150多年来，我们一直致力于为所有依赖我们的人们带来改变。我们会定期在我们的网站www.Pfizer.com上发布对投资者可能重要的信息。此外，要了解更多信息，请访问我们的网站www.Pfizer.com，并在Twitter上关注我们@Pfizer和@Pfizer News，LinkedIn，YouTube，并在Facebook.com/Pfizer上关注我们。</p><p>  The information contained in this release is as of November 20, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p><p>本新闻稿包含的信息截至2020年11月20日。由于新信息或未来事件或发展，辉瑞公司不承担更新本新闻稿中包含的前瞻性陈述的义务。</p><p> This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine, the BNT162 mRNA vaccine program and modRNA candidate BNT162b2 (including qualitative assessments of available data, potential benefits, expectations for clinical trials, the submission of a request for Emergency Use Authorization and other regulatory submissions, the anticipated timing of regulatory submissions, regulatory approval or authorization and anticipated manufacturing, distribution and supply), that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with clinical data (including the Phase 3 data), including the possibility of unfavorable new preclinical or clinical trial data and further analyses of existing preclinical or clinical trial data; the ability to produce comparable clinical or other results, including the rate of vaccine effectiveness and safety and tolerability profile observed to date, in additional analyses of the Phase 3 trial or in larger, more diverse populations upon commercialization; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from the BNT162 mRNA vaccine program will be published in scientific journal publications and, if so, when and with what modifications; whether regulatory authorities will be satisfied with the design of and results from these and any future preclinical and clinical studies; whether and when any other biologics license and/or emergency use authorization applications may be filed in any jurisdictions for BNT162b2 or any other potential vaccine candidates; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the vaccine candidate’s benefits outweigh its known risks and determination of the vaccine candidate’s efficacy and, if approved, whether it will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of a vaccine, including development of products or therapies by other companies; disruptions in the relationships between us and our collaboration partners or third-party suppliers; risks related to the availability of raw materials to manufacture a vaccine; challenges related to our vaccine candidate’s ultra-low temperature formulation and attendant storage, distribution and administration requirements, including risks related to handling after delivery by Pfizer; the risk that we may not be able to successfully develop non-frozen formulations; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine candidate within the projected time periods indicated; whether and when additional supply agreements will be reached; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities and uncertainties regarding the commercial impact of any such recommendations; uncertainties regarding the impact of COVID-19 on Pfizer’s business, operations and financial results; and competitive developments.</p><p>本新闻稿包含有关辉瑞公司抗击COVID-19的努力，BioNTech与辉瑞公司合作开发潜在的COVID-19疫苗，BNT162 mRNA疫苗计划和modRNA候选BNT162b2的前瞻性信息（包括对可用数据的定性评估，潜在收益） ，对临床试验的期望，对紧急使用授权的请求的提交以及其他法规的提交，法规提交的预计时间，法规的批准或授权以及预期的制造，分销和供应），其中涉及可能导致实际风险的重大风险和不确定性结果与此类陈述所表达或暗示的结果存在重大差异。风险和不确定因素包括研发中固有的不确定因素，包括满足预期临床终点的能力，临床试验的开始和/或完成日期，法规提交日期，法规批准日期和/或启动日期等。以及与临床数据（包括3期数据）相关的风险，包括不利的新临床前或临床试验数据的可能性以及对现有临床前或临床试验数据的进一步分析；在进行3期临床试验的其他分析中或在商业化后的更大，更多人群中产生可比较的临床或其他结果的能力，包括迄今为止观察到的疫苗有效性，安全性和耐受性的比率；临床试验数据受到不同解释和评估的风险，包括在同行评审/发表过程中，在整个科学界以及在监管机构中； BNT162 mRNA疫苗计划的数据是否以及何时将在科学期刊出版物上发表，如果是，则何时以及进行何种修改；监管机构是否会对这些以及将来的临床前和临床研究的设计和结果感到满意；是否以及何时在任何司法管辖区针对BNT162b2或任何其他潜在的疫苗候选者提交任何其他生物制剂许可证和/或紧急使用授权申请；监管机构是否批准以及何时批准任何此类申请，这将取决于多种因素，包括确定候选疫苗的益处是否超过其已知风险，并确定候选疫苗的功效，以及如果批准，是否将商业上成功；监管机构做出的影响标签，制造工艺，安全性和/或其他可能影响疫苗可用性或商业潜力的决定，包括其他公司开发产品或疗法的决定；我们与我们的合作伙伴或第三方供应商之间的关系中断；与生产疫苗所需原料有关的风险；与我们的候选疫苗的超低温制剂以及随之而来的存储，分发和管理要求有关的挑战，包括与辉瑞公司交付后处理有关的风险；我们可能无法成功开发非冷冻配方的风险；我们可能无法及时建立或扩大生产能力或无法获得与全球对任何潜在批准疫苗的需求相称的物流或供应渠道的风险，这会对我们提供估计剂量的能力产生负面影响在所示的预计时间段内我们的候选疫苗；是否以及何时达成附加供应协议；从疫苗技术委员会和其他公共卫生当局获得建议的能力的不确定性，以及任何此类建议的商业影响的不确定性；有关COVID-19对辉瑞公司业务，运营和财务业绩的影响的不确定性；和竞争性发展。</p><p> A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at  www.sec.gov and  www.pfizer.com.</p><p>辉瑞在截至2019年12月31日的财年的10-K表格年度报告以及其在10-Q表格的后续报告中均提供了有关风险和不确定性的进一步说明，其中包括标题为``风险因素''和“可能影响未来结果的前瞻性信息和因素”，以及其随后的有关表格8-K的报告，所有这些报告均已提交给美国证券交易委员会，可在www.sec.gov和www.cn上获得。 pfizer.com。</p><p>  Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit   www.BioNTech.de.</p><p>生物制药新技术公司是下一代免疫疗法公司，致力于治疗癌症和其他严重疾病的新型疗法。该公司利用各种计算发现和治疗药物平台来快速开发新型生物药物。其广泛的肿瘤产品候选产品组合包括个性化和现成的基于mRNA的疗法，创新的嵌合抗原受体T细胞，双特异性检查点免疫调节剂，靶向的癌症抗体和小分子。基于其在mRNA疫苗开发和内部制造能力方面的深厚专业知识，BioNTech及其合作者正在通过多种肿瘤学途径，为一系列传染病开发多种mRNA疫苗候选药物。 BioNTech已与多家全球制药合作伙伴建立了广泛的合作关系，其中包括Genmab，赛诺菲，拜耳动物保健，Genentech，罗氏集团的成员，Regeneron，Genevant，复星医药和辉瑞。有关更多信息，请访问www.BioNTech.de。</p><p>  This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning: BioNTech’s efforts to combat COVID-19; the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine; our expectations regarding the potential characteristics of BNT162b2 in our Phase 2/3 trial and/or in commercial use based on data observations to date; the expected timepoint for additional readouts on efficacy data of BNT162b2 in our Phase 2/3 trial; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; the timing for submission of data for, or receipt of, any marketing approval or Emergency Use Authorization; the timing for submission of manufacturing data to the FDA; our contemplated shipping and storage plan, including our estimated product shelflife at various temperatures; and the ability of BioNTech to supply the quantities of BNT162 to support clinical development and, if approved, market demand, including our production estimates for 2020 and 2021. Any forward-looking statements in this press release are based on BioNTech current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the ability to meet the pre-defined endpoints in clinical trials; competition to create a vaccine for COVID-19; the ability to produce comparable clinical or other results, including our stated rate of vaccine effectiveness and safety and tolerability profile observed to date, in the remainder of the trial or in larger, more diverse populations upon commercialization; the ability to effectively scale our productions capabilities; and other potential difficulties. For a discussion of these and other risks and uncertainties, see BioNTech’s Quarterly Report for the Three and Nine Months Ended September 30, 2020, filed as Exhibit 99.2 to its Current Report on Form 6-K filed with the SEC on November 10, which is available on the SEC’s website at  www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.</p><p>本新闻稿包含1995年《私人证券诉讼改革法案》所定义的BioNTech的“前瞻性声明”。这些前瞻性声明可能包括但不限于涉及以下方面的声明：BioNTech对抗COVID-19的努力; BioNTech与辉瑞公司之间的合作，以开发潜在的COVID-19疫苗；根据迄今为止的数据观察，我们对BNT162b2在我们的2/3期试验和/或商业用途中潜在特性的期望；在我们的2/3期试验中进一步读取BNT162b2功效数据的预期时间点；临床数据的性质，这取决于正在进行的同行审查，监管审查和市场解释；为任何营销批准或紧急使用授权提交数据或接收数据的时间；向FDA提交制造数据的时间；我们计划的运输和存储计划，包括我们在各种温度下的估计产品保质期；以及BioNTech提供一定数量的BNT162来支持临床开发以及经批准的市场需求的能力，包括我们对2020年和2021年的产量估计。本新闻稿中的任何前瞻性陈述均基于BioNTech当前的期望和信念。未来事件，并受到多种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与此类前瞻性陈述中所阐明或暗示的结果存在重大不利差异。这些风险和不确定性包括但不限于：满足临床试验中预定终点的能力；竞争生产COVID-19疫苗；在其余的试验中或在商业化后的更大，更多样化的人群中产生可比较的临床或其他结果的能力，包括我们迄今观察到的所述疫苗有效性，安全性和耐受性描述的比率；有效扩大我们的生产能力的能力；和其他潜在的困难。有关这些及其他风险和不确定性的讨论，请参阅《 BioNTech截至2020年9月30日的三个月和九个月的季度报告》，其11月10日提交给SEC的6-K表当前报告的附件99.2列出了该报告。可在SEC网站www.sec.gov上找到。本新闻稿中的所有信息均为发布之日，除非法律要求，否则BioNTech不承担更新此信息的责任。</p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization">https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-submit-emergency-use-authorization</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/covid/">#covid</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/submits/">#submits</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/疫苗/">#疫苗</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy; 2020 diglog.com </div></div></body></html>